Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

265 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Investigation of Hematuria.
Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. Bolenz C, et al. Dtsch Arztebl Int. 2018 Nov 30;115(48):801-807. doi: 10.3238/arztebl.2018.0801. Dtsch Arztebl Int. 2018. PMID: 30642428 Free PMC article. Review.
Prediction of Locally Advanced Urothelial Carcinoma of the Bladder Using Clinical Parameters before Radical Cystectomy--A Prospective Multicenter Study.
Martini T, Aziz A, Roghmann F, Rink M, Chun FK, Fisch M, Trojan L, Hakenberg OW, Zastrow S, Wirth MP, Moersdorf J, Brookman-May S, Stief CG, Haferkamp A, Wagenlehner F, Hohenfellner M, Herrmann E, Lusuardi L, Grimm MO, Müller SC, Roigas J, Bastian PJ, Gierth M, Burger M, Pycha A, Seitz C, May M, Bolenz C. Martini T, et al. Among authors: bolenz c. Urol Int. 2016;96(1):57-64. doi: 10.1159/000433606. Epub 2015 Jul 1. Urol Int. 2016. PMID: 26139354
The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.
Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C. Martini T, et al. Among authors: bolenz c. Clin Genitourin Cancer. 2017 Jun;15(3):356-362. doi: 10.1016/j.clgc.2016.09.003. Epub 2016 Sep 19. Clin Genitourin Cancer. 2017. PMID: 27765613
SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE. Retz M, et al. Among authors: bolenz c. Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7. Eur J Cancer. 2019. PMID: 30529901 Clinical Trial.
In Reply.
Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO. Bolenz C, et al. Dtsch Arztebl Int. 2019 Mar 8;116(11):192-193. doi: 10.3238/arztebl.2019.0192b. Dtsch Arztebl Int. 2019. PMID: 31014454 Free PMC article. No abstract available.
Discriminative capacity of guideline recommendations in the assessment of patients with asymptomatic microhematuria.
Kuckuck EC, Hennenlotter J, Todenhöfer T, Brünn LA, Rass GC, Stenzl A, Hakenberg OW, Roghmann F, Goebell PJ, Grimm MO, Pycha A, Bolenz C, Burger M, Benderska-Söder N, Schmitz-Dräger BJ. Kuckuck EC, et al. Among authors: bolenz c. Urol Oncol. 2023 May;41(5):254.e1-254.e8. doi: 10.1016/j.urolonc.2022.08.011. Epub 2022 Oct 21. Urol Oncol. 2023. PMID: 36274029
Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advanced transitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial.
Grimm MO, Grün CB, Niegisch G, Pichler M, Roghmann F, Schmitz-Dräger B, Baretton G, Schmitz M, Bolenz C, Foller S, Leucht K, Schumacher U, Schostak M, Meran J, Loidl W, Zengerling F. Grimm MO, et al. Among authors: bolenz c. Lancet Oncol. 2023 Apr;24(4):347-359. doi: 10.1016/S1470-2045(23)00053-0. Epub 2023 Feb 28. Lancet Oncol. 2023. PMID: 36868252 Clinical Trial.
265 results